266 related articles for article (PubMed ID: 33396627)
1. Proteomics of Muscle Microdialysates Identifies Potential Circulating Biomarkers in Facioscapulohumeral Muscular Dystrophy.
Corasolla Carregari V; Monforte M; Di Maio G; Pieroni L; Urbani A; Ricci E; Tasca G
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396627
[TBL] [Abstract][Full Text] [Related]
2. Muscle Microdialysis to Investigate Inflammatory Biomarkers in Facioscapulohumeral Muscular Dystrophy.
Tasca G; Monforte M; Corbi M; Granata G; Lucchetti D; Sgambato A; Ricci E
Mol Neurobiol; 2018 Apr; 55(4):2959-2966. PubMed ID: 28456937
[TBL] [Abstract][Full Text] [Related]
3. A Targeted Approach for Evaluating DUX4-Regulated Proteins as Potential Serum Biomarkers for Facioscapulohumeral Muscular Dystrophy Using Immunoassay Proteomics.
Campbell AE; Arjomand J; King OD; Tawil R; Jagannathan S
J Neuromuscul Dis; 2023; 10(6):1031-1040. PubMed ID: 37899061
[TBL] [Abstract][Full Text] [Related]
4. Identification of Serum Interleukin 6 Levels as a Disease Severity Biomarker in Facioscapulohumeral Muscular Dystrophy.
Gros M; Nunes AM; Daoudlarian D; Pini J; Martinuzzi E; Barbosa S; Ramirez M; Puma A; Villa L; Cavalli M; Grecu N; Garcia J; Siciliano G; Solé G; Juntas-Morales R; Jones PL; Jones T; Glaichenhaus N; Sacconi S
J Neuromuscul Dis; 2022; 9(1):83-93. PubMed ID: 34459413
[TBL] [Abstract][Full Text] [Related]
5. A cross sectional study of two independent cohorts identifies serum biomarkers for facioscapulohumeral muscular dystrophy (FSHD).
Petek LM; Rickard AM; Budech C; Poliachik SL; Shaw D; Ferguson MR; Tawil R; Friedman SD; Miller DG
Neuromuscul Disord; 2016 Jul; 26(7):405-13. PubMed ID: 27185459
[TBL] [Abstract][Full Text] [Related]
6. DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation.
Banerji CRS; Panamarova M; Zammit PS
Hum Mol Genet; 2020 Aug; 29(14):2285-2299. PubMed ID: 32242220
[TBL] [Abstract][Full Text] [Related]
7. Skeletal muscle regeneration in facioscapulohumeral muscular dystrophy is correlated with pathological severity.
Banerji CRS; Henderson D; Tawil RN; Zammit PS
Hum Mol Genet; 2020 Sep; 29(16):2746-2760. PubMed ID: 32744322
[TBL] [Abstract][Full Text] [Related]
8. Muscle fibrosis as a prognostic biomarker in facioscapulohumeral muscular dystrophy: a retrospective cohort study.
Ragozzino E; Bortolani S; Di Pietro L; Papait A; Parolini O; Monforte M; Tasca G; Ricci E
Acta Neuropathol Commun; 2023 Oct; 11(1):165. PubMed ID: 37849014
[TBL] [Abstract][Full Text] [Related]
9. Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers.
van den Heuvel A; Lassche S; Mul K; Greco A; San León Granado D; Heerschap A; Küsters B; Tapscott SJ; Voermans NC; van Engelen BGM; van der Maarel SM
Sci Rep; 2022 Jan; 12(1):1426. PubMed ID: 35082321
[TBL] [Abstract][Full Text] [Related]
10. Profiling Serum Antibodies Against Muscle Antigens in Facioscapulohumeral Muscular Dystrophy Finds No Disease-Specific Autoantibodies.
Greco A; Straasheijm KR; Mul K; van den Heuvel A; van der Maarel SM; Joosten LAB; van Engelen BGM; Pruijn GJM
J Neuromuscul Dis; 2021; 8(5):801-814. PubMed ID: 34024774
[TBL] [Abstract][Full Text] [Related]
11. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.
Banerji CRS; Zammit PS
Hum Mol Genet; 2019 Jul; 28(13):2224-2236. PubMed ID: 31067297
[TBL] [Abstract][Full Text] [Related]
12. Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models.
Nunes AM; Ramirez M; Jones TI; Jones PL
Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34338285
[TBL] [Abstract][Full Text] [Related]
13. Muscle MRI findings in facioscapulohumeral muscular dystrophy.
Gerevini S; Scarlato M; Maggi L; Cava M; Caliendo G; Pasanisi B; Falini A; Previtali SC; Morandi L
Eur Radiol; 2016 Mar; 26(3):693-705. PubMed ID: 26115655
[TBL] [Abstract][Full Text] [Related]
14. MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD.
Wang LH; Friedman SD; Shaw D; Snider L; Wong CJ; Budech CB; Poliachik SL; Gove NE; Lewis LM; Campbell AE; Lemmers RJFL; Maarel SM; Tapscott SJ; Tawil RN
Hum Mol Genet; 2019 Feb; 28(3):476-486. PubMed ID: 30312408
[TBL] [Abstract][Full Text] [Related]
15. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
[TBL] [Abstract][Full Text] [Related]
16. Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles.
Tasca G; Pescatori M; Monforte M; Mirabella M; Iannaccone E; Frusciante R; Cubeddu T; Laschena F; Ottaviani P; Ricci E
PLoS One; 2012; 7(6):e38779. PubMed ID: 22719944
[TBL] [Abstract][Full Text] [Related]
17. Perturbation of muscle metabolism in patients with muscular dystrophy in early or acute phase of disease: In vitro, high resolution NMR spectroscopy based analysis.
Srivastava NK; Yadav R; Mukherjee S; Sinha N
Clin Chim Acta; 2018 Mar; 478():171-181. PubMed ID: 29278724
[TBL] [Abstract][Full Text] [Related]
18. Correlation between low FAT1 expression and early affected muscle in facioscapulohumeral muscular dystrophy.
Mariot V; Roche S; Hourdé C; Portilho D; Sacconi S; Puppo F; Duguez S; Rameau P; Caruso N; Delezoide AL; Desnuelle C; Bessières B; Collardeau S; Feasson L; Maisonobe T; Magdinier F; Helmbacher F; Butler-Browne G; Mouly V; Dumonceaux J
Ann Neurol; 2015 Sep; 78(3):387-400. PubMed ID: 26018399
[TBL] [Abstract][Full Text] [Related]
19. Quantitative proteomics reveals key roles for post-transcriptional gene regulation in the molecular pathology of facioscapulohumeral muscular dystrophy.
Jagannathan S; Ogata Y; Gafken PR; Tapscott SJ; Bradley RK
Elife; 2019 Jan; 8():. PubMed ID: 30644821
[TBL] [Abstract][Full Text] [Related]
20. Interplay between mitochondrial reactive oxygen species, oxidative stress and hypoxic adaptation in facioscapulohumeral muscular dystrophy: Metabolic stress as potential therapeutic target.
Heher P; Ganassi M; Weidinger A; Engquist EN; Pruller J; Nguyen TH; Tassin A; Declèves AE; Mamchaoui K; Banerji CRS; Grillari J; Kozlov AV; Zammit PS
Redox Biol; 2022 May; 51():102251. PubMed ID: 35248827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
